查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生物製品市場：2024-2034
市場調查報告書
商品編碼
1386923

全球生物製品市場：2024-2034

Biologics Market Report 2024-2034
出版日期: | 出版商: Visiongain Reports Ltd. | 英文 312 Pages | 商品交期: 最快1-2個工作天內

價格

到 2034 年，全球生物製品市場規模預計將以 8.5% 的複合年增長率成長。

再生醫學和細胞生物學的進步推動市場成長

細胞生物學和再生醫學的進步為針對多種疾病（包括心血管、腫瘤、代謝和肌肉骨骼疾病）的幹細胞療法奠定了堅實的基礎，推動了市場成長。處於領先地位。 這些突破性的治療方法為世界各地的患者提供了解決複雜醫療挑戰的創新策略的可能性。 這一領域的持續探索和創新有望實現進一步的裡程碑，為未來有效管理甚至消除疾病鋪平道路。

生物製劑專利到期所帶來的挑戰

隨著前幾代生物製劑的專利到期以及生物相似藥很快進入市場，預計競爭將會加劇。 生物相似藥旨在複製已批准的生物產品的質量，隨著各國政府尋求降低醫療保健成本，生物相似藥在全球範圍內獲得了發展勢頭。

本報告調查了全球生物製品市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析以及競爭格局。其中彙編了主要生物製品的概況公司。

目錄

第 1 章報告概述

第 2 章執行摘要

第三章市場概述

  • 主要調查結果
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 市場機會
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • PEST分析

第 4 章生物製劑市場分析：依產品

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 單株抗體
    • 人類
    • 人性化
    • 奇美拉
    • 老鼠
  • 疫苗
  • 重組蛋白
  • 再生醫學
    • 組織工程產品
    • 細胞療法
    • 基因治療
  • 其他

第 5 章生物製品市場分析：依應用

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 腫瘤
  • 傳染病
  • 自體免疫疾病
  • 血液疾病
  • 心血管疾病
  • 其他

第 6 章生物製品市場分析：依製造類型

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 外包
  • 內部

第 7 章生物製劑市場分析：依最終使用者

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 醫院
  • 專業中心
  • 其他

第 8 章生物製劑市場分析：依地區

  • 主要調查結果
  • 市場規模趨勢與預測

第九章北美生物製品市場分析

第 10 章歐洲生物製品市場分析

第 11 章亞太生物製品市場分析

第十二章中東與非洲生物製品市場分析

第十三章拉丁美洲生物製品市場分析

第十四章公司簡介

  • 競爭狀況
  • 戰略展望
  • Johnson &Johnson
  • F. Hoffmann-La Roche AG
  • Amgen Inc.
  • AbbVie Inc.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Merck &Co.
  • AstraZeneca plc
  • Sanofi
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Celltrion, Inc.
  • Biogen Inc.

第 15 章一般性評論/建議

  • Visiongain 概述
  • 對進入市場的公司的建議
Product Code: PHA1298

The global Biologics Market is projected to grow at a CAGR of 8.5% by 2034 .

“The Biologics Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advances in Regenerative Medicine and Cell Biology Driving Market Growth

Advancements in cell biology and regenerative medicine are driving market growth by laying a robust foundation for stem cell-based therapies targeting a range of disorders, including cardiovascular, oncological, metabolic, and musculoskeletal conditions. These groundbreaking treatments offer global patients the potential for transformative strategies in handling complex medical challenges. Continued exploration and innovation in this field are poised to achieve further milestones, ushering in a future where debilitating illnesses can be effectively managed, and in some cases, even eliminated. Companies like Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics leverage CRISPR-Cas9 gene editing technology for potential gene therapies and regenerative medicine applications, aiming to rectify genetic disorders at the molecular level. Additionally, Vericel's FDA-approved MACI (Matrix-Induced Autologous Chondrocyte Implantation) utilizes a patient's own cells to repair knee cartilage defects.

Challenges Posed by Patent Expiration for Biologics

The expiration of patents on the initial biologics generation is paving the way for increased competition as biosimilars are poised to enter the market soon. Biosimilars, designed to replicate the qualities of previously approved biologic therapies, are gaining momentum worldwide, driven by governments aiming to reduce healthcare costs. Notably, the Central Drugs Standard Control Organization (CDSCO) in India has introduced the "Guidelines on Similar Biologics" to boost the Indian biosimilars industry. The biologics field in biotechnology is rapidly evolving, with over 60% dedicated to treating diabetes, autoimmune disorders, and cancer, resulting in high and escalating costs. Recognizing the barrier posed by these high prices, the World Health Organization (WHO) highlights an opportunity for generic drug manufacturers to produce biosimilar versions as patents expire. Generic drug producers are actively seeking biologics with impending patent expirations, with 230 drug patents set to expire between 2021 and 2025. Notable biologics expiring in 2024 include PERJETA (Pertuzumab), VYROLOGIX (Leronlimab), and STELARA (Ustekinumab). The Center for Biosimilars notes that while biologics currently constitute half of the oncology pharmaceutical industry, the expiration of nearly 20 oncology biologics' patents by 2024 could lead to increased use of biosimilars in cancer treatment, contributing to lower overall costs.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the biologics market evolving?
  • What is driving and restraining the biologics market?
  • How will each biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each biologics submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading biologics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the biologics projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of biologics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the biologics market?
  • Where is the biologics market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biologics market today, and over the next 10 years:

  • Our 312-page report provides 127 tables and 213 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the biologics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product Outlook

  • Monoclonal Antibodies
    • Human
    • Humanized
    • Chimeric
    • Murine
  • Vaccines
  • Recombinant Proteins
  • Regenerative Medicine
    • Tissue Engineered Products
    • Cell Therapy
    • Gene Therapies
  • Others

Application

  • Oncology
  • Infectious Diseases
  • Autoimmune Disease
  • Haematological Disorder
  • Cardiovascular Disorders
  • Others

Manufacturing Type

  • Outsource
  • In-house

End-users

  • Hospitals
  • Speciality Centres
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Biologics Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Celltrion, Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi

Overall world revenue for Biologics Market, 2024 to 2034 in terms of value the market will surpass US$470.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Biologics Market, 2024 to 2034” report help you?

In summary, our 310+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Biologics Market, 2024 to 2034 Market, with forecasts for product, application, manufacturing type, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 22 key national markets - See forecasts for the Biologics Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Biologics Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Biologics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Biologics Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Rising Demand for Biologics
      • 3.2.1.2 High Funding for Biomedical Research
      • 3.2.1.3 Increase in Number of Elderly Population will Drive the Market Growth
      • 3.2.1.4 Increasing Prevalence of Chronic Diseases
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Patent Expiration for Biologics
      • 3.2.2.2 High Cost of Biologics
      • 3.2.2.3 High Stringency and Low Turnover for Clinical Trials
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Emerging Economies Expansion and Prioritisation of R&D
      • 3.2.3.2 Growing Significance of Genomics and Proteomics
      • 3.2.3.3 Collaboration, M&A, and Partnerships among Biologics Companies
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Biologics Market Analysis by Product

  • 4.1 Key Findings
  • 4.2 Product Segment: Market Attractiveness Index
  • 4.3 Biologics Market Size Estimation and Forecast by Product
  • 4.4 Monoclonal Antibodies
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.3 Human
      • 4.4.3.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.4.3.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.4 Humanized
      • 4.4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.5 Chimeric
      • 4.4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.6 Murine
      • 4.4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Vaccines
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Recombinant Proteins
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Regenerative Medicine
    • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)
    • 4.7.3 Tissue Engineered Products
      • 4.7.3.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.7.3.2 Market Share by Region, 2024 & 2034 (%)
    • 4.7.4 Cell Therapy
      • 4.7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.7.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.7.5 Gene Therapies
      • 4.7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
      • 4.7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.8 Others
    • 4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.8.2 Market Share by Region, 2024 & 2034 (%)

5 Biologics Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Biologics Market Size Estimation and Forecast by Application
  • 5.4 Oncology
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Infectious Diseases
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Autoimmune Diseases
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Haematological Disorders
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Cardiovascular Disorders
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Biologics Market Analysis by Manufacturing Type

  • 6.1 Key Findings
  • 6.2 Manufacturing Type Segment: Market Attractiveness Index
  • 6.3 Biologics Market Size Estimation and Forecast by Manufacturing Type
  • 6.4 Outsource
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 In-house
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Biologics Market Analysis by End-users

  • 7.1 Key Findings
  • 7.2 End-users Segment: Market Attractiveness Index
  • 7.3 Biologics Market Size Estimation and Forecast by End-users
  • 7.4 Hospitals
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Speciality Centres
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Others
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Biologics Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Biologics Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Biologics Market Attractiveness Index
  • 9.3 North America Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 North America Biologics Market Size Estimation and Forecast by Country
  • 9.5 North America Biologics Market Size Estimation and Forecast by Product
  • 9.6 North America Biologics Market Size Estimation and Forecast by Application
  • 9.7 North America Biologics Market Size Estimation and Forecast by Manufacturing Type
  • 9.8 North America Biologics Market Size Estimation and Forecast by End-users
  • 9.9 U.S. Biologics Market Analysis
  • 9.10 Canada Biologics Market Analysis

10 Europe Biologics Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Biologics Market Attractiveness Index
  • 10.3 Europe Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Europe Biologics Market Size Estimation and Forecast by Country
  • 10.5 Europe Biologics Market Size Estimation and Forecast by Product
  • 10.6 Europe Biologics Market Size Estimation and Forecast by Application
  • 10.7 Europe Biologics Market Size Estimation and Forecast by Manufacturing Type
  • 10.8 Europe Biologics Market Size Estimation and Forecast by End-users
  • 10.9 Germany Biologics Market Analysis
  • 10.10 UK Biologics Market Analysis
  • 10.11 France Biologics Market Analysis
  • 10.12 Italy Biologics Market Analysis
  • 10.13 Spain Biologics Market Analysis
  • 10.14 Russia Biologics Market Analysis
  • 10.15 Rest of Europe Biologics Market Analysis

11 Asia Biologics Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Biologics Market Attractiveness Index
  • 11.3 Asia Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Asia Biologics Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Biologics Market Size Estimation and Forecast by Product
  • 11.6 Asia Pacific Biologics Market Size Estimation and Forecast by Application
  • 11.7 Asia Pacific Biologics Market Size Estimation and Forecast by Manufacturing Type
  • 11.8 Asia Pacific Biologics Market Size Estimation and Forecast by End-users
  • 11.9 Japan Biologics Market Analysis
  • 11.10 China Biologics Market Analysis
  • 11.11 India Biologics Market Analysis
  • 11.12 Australia Biologics Market Analysis
  • 11.13 South Korea Biologics Market Analysis
  • 11.14 Rest of Asia Biologics Market Analysis

12 Latin America Biologics Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Biologics Market Attractiveness Index
  • 12.3 Latin America Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Latin America Biologics Market Size Estimation and Forecast by Country
  • 12.5 Latin America Biologics Market Size Estimation and Forecast by Product
  • 12.6 Latin America Biologics Market Size Estimation and Forecast by Application
  • 12.7 Latin America Biologics Market Size Estimation and Forecast by Manufacturing Type
  • 12.8 Latin America Biologics Market Size Estimation and Forecast by End-users
  • 12.9 Brazil Biologics Market Analysis
  • 12.10 Mexico Biologics Market Analysis
  • 12.11 Argentina Biologics Market Analysis
  • 12.12 Rest of Latin America Biologics Market Analysis

13 MEA Biologics Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Biologics Market Attractiveness Index
  • 13.3 MEA Biologics Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 MEA Biologics Market Size Estimation and Forecast by Country
  • 13.5 MEA Biologics Market Size Estimation and Forecast by Product
  • 13.6 MEA Biologics Market Size Estimation and Forecast by Application
  • 13.7 MEA Biologics Market Size Estimation and Forecast by Manufacturing Type
  • 13.8 MEA Biologics Market Size Estimation and Forecast by End-users
  • 13.9 GCC Biologics Market Analysis
  • 13.10 South Africa Biologics Market Analysis
  • 13.11 Rest of MEA Biologics Market Analysis

14 Company Profiles

  • 14.1 Company Share Analysis, 2022
  • 14.2 Strategic Outlook
  • 14.3 Johnson & Johnson
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue,2017-2022
      • 14.3.3.2 R&D,2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
      • 14.3.3.4 Business Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 F. Hoffmann-La Roche AG
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2022
      • 14.4.3.2 R&D, 2017-2022
      • 14.4.3.3 Regional Market Shares, 2022
      • 14.4.3.4 Business Market Shares, 2022
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Amgen Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
      • 14.5.3.3 Regional Market Shares, 2022
      • 14.5.3.4 Business Market Shares, 2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 AbbVie Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2017-2022
      • 14.6.3.2 R&D, 2017-2022
      • 14.6.3.3 Regional Market Shares, 2022
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Novo Nordisk A/S
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2017-2022
      • 14.7.3.2 R&D, 2017-2022
      • 14.7.3.3 Regional Market Shares, 2022
      • 14.7.3.4 Business Market Shares, 2022
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Eli Lilly and Company
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2017-2022
      • 14.8.3.2 R&D, 2017-2022
      • 14.8.3.3 Regional Market Shares, 2022
      • 14.8.3.4 Business Market Shares, 2022
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Bristol-Myers Squibb Company
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2017-2022
      • 14.9.3.2 R&D, 2017-2022
      • 14.9.3.3 Regional Market Shares, 2022
      • 14.9.3.4 Business Market Shares, 2022
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Merck & Co.
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 R&D, 2017-2022
      • 14.10.3.3 Regional Market Shares, 2022
      • 14.10.3.4 Business Market Shares, 2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 AstraZeneca plc
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2022
      • 14.11.3.2 R&D, 2017-2022
      • 14.11.3.3 Regional Market Shares, 2022
      • 14.11.3.4 Business Market Shares, 2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Sanofi
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
      • 14.12.3.3 Regional Market Shares, 2022
      • 14.12.3.4 Business Market Shares, 2022
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Pfizer Inc.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2022
      • 14.13.3.2 R&D, 2017-2022
      • 14.13.3.3 Regional Market Shares, 2023
      • 14.13.3.4 Business Market Shares, 2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Regeneron Pharmaceuticals, Inc.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue,2017-2022
      • 14.14.3.2 R&D,2017-2022
      • 14.14.3.3 Business Market Shares, 2022
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Gilead Sciences, Inc.
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue,2017-2022
      • 14.15.3.2 R&D,2017-2022
      • 14.15.3.3 Regional Market Shares, 2022
      • 14.15.3.4 Business Market Shares, 2022
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Celltrion, Inc.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Biogen Inc.
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2017-2022
      • 14.17.3.2 R&D, 2017-2022
      • 14.17.3.3 Regional Market Shares, 2022
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Biologics Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 Collaboration, M&A, and Partnerships among Biologics Companies
  • Table 3 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 4 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 5 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 7 Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 8 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 9 Human Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 10 Humanized Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 11 Chimeric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 12 Murine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 13 Vaccines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 14 Recombinant Proteins Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 15 Regenerative Medicine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 16 Tissue Engineered Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 17 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 18 Gene Therapies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 20 Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 21 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 22 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 23 Autoimmune Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 24 Haematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 25 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 26 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 27 Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 28 Outsource Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 29 In-house Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 30 Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 31 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 32 Speciality Centres Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 33 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 34 Biologics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 35 North America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 36 North America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 37 North America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 38 North America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 39 North America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 40 U.S. Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 41 Canada Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 42 Europe Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 43 Europe Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 44 Europe Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 45 Europe Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 46 Europe Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 47 Germany Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 48 UK Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 49 France Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 50 Italy Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 51 Spain Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 52 Russia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 53 Rest of Europe Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 54 Asia Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 55 Asia Pacific Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 56 Asia Pacific Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 57 Asia Pacific Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 58 Asia Pacific Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 59 Japan Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 60 China Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 61 India Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 62 Australia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 63 South Korea Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 64 Rest of Asia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 65 Latin America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 66 Latin America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 67 Latin America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 68 Latin America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 69 Latin America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 70 Brazil Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 71 Mexico Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 72 Argentina Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 73 Rest of Latin America Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 74 MEA Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 75 MEA Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 76 MEA Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 77 MEA Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 78 MEA Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 79 GCC Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 80 South Africa Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 81 Rest of MEA Biologics Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 82 Strategic Outlook
  • Table 83 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 Johnson & Johnson: Product Benchmarking
  • Table 85 Johnson & Johnson: Strategic Outlook
  • Table 86 F. Hoffmann-La Roche AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87 F. Hoffmann-La Roche AG: Product Benchmarking
  • Table 88 F. Hoffmann-La Roche AG: Strategic Outlook
  • Table 89 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Amgen Inc.: Product Benchmarking
  • Table 91 Amgen Inc. Strategic Outlook
  • Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 AbbVie Inc.: Product Benchmarking
  • Table 94 AbbVie Inc.: Strategic Outlook
  • Table 95 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Novo Nordisk A/S: Product Benchmarking
  • Table 97 Novo Nordisk A/S Strategic Outlook
  • Table 98 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Eli Lilly and Company: Product Benchmarking
  • Table 100 Eli Lilly and Company Strategic Outlook
  • Table 101 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Bristol-Myers Squibb Company: Product Benchmarking
  • Table 103 Bristol-Myers Squibb Company Strategic Outlook
  • Table 104 Merck & Co.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Merck & Co.: Product Benchmarking
  • Table 106 Merck & Co.: Strategic Outlook
  • Table 107 AstraZeneca plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 AstraZeneca plc: Product Benchmarking
  • Table 109 AstraZeneca plc Strategic Outlook
  • Table 110 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Sanofi: Product Benchmarking
  • Table 112 Sanofi Strategic Outlook
  • Table 113 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 Pfizer Inc.: Product Benchmarking
  • Table 115 Pfizer Inc.: Strategic Outlook
  • Table 116 Regeneron Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 Regeneron Pharmaceuticals, Inc.: Product Benchmarking
  • Table 118 Regeneron Pharmaceuticals, Inc.: Strategic Outlook
  • Table 119 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 Gilead Sciences, Inc.: Product Benchmarking
  • Table 121 Gilead Sciences, Inc.: Strategic Outlook
  • Table 122 Celltrion, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 123 Celltrion, Inc.: Product Benchmarking
  • Table 124 Celltrion, Inc. Strategic Outlook
  • Table 125 Biogen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 126 Biogen Inc.: Product Benchmarking
  • Table 127 Biogen Inc. Strategic Outlook
  •  

List of Figures

  • Figure 1 Biologics Market Segmentation
  • Figure 2 Biologics Market by Product: Market Attractiveness Index
  • Figure 3 Biologics Market by Application: Market Attractiveness Index
  • Figure 4 Biologics Market by Manufacturing Type: Market Attractiveness Index
  • Figure 5 Biologics Market by End-users: Market Attractiveness Index
  • Figure 6 Biologics Market Attractiveness Index by Region
  • Figure 7 Biologics Market: Market Dynamics
  • Figure 8 NIH Program Level Budget 2016-2023 (US$ Bn)
  • Figure 9 Global Population Aged 65+, 2022 (Million)
  • Figure 10 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): "V" Shaped Recovery
  • Figure 11 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): "U" Shaped Recovery
  • Figure 12 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): "W" Shaped Recovery
  • Figure 13 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %): "L" Shaped Recovery
  • Figure 14 Biologics Market: Porter's Five Forces Analysis
  • Figure 15 Biologics Market: PEST Analysis
  • Figure 16 Biologics Market by Product: Market Attractiveness Index
  • Figure 17 Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 18 Biologics Share Forecast by Product, 2024, 2029, 2034 (%)
  • Figure 19 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 20 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Human Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 22 Human Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Humanized Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 24 Humanized Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Chimeric Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 26 Chimeric Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Murine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 28 Murine Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Vaccines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 30 Vaccines Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Recombinant Proteins Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 32 Recombinant Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Regenerative Medicine Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 34 Regenerative Medicine Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Tissue Engineered Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 36 Tissue Engineered Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 38 Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Gene Therapies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 40 Gene Therapies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 42 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 43 Biologics Market by Application: Market Attractiveness Index
  • Figure 44 Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 45 Biologics Share Forecast by Application, 2024, 2029, 2034 (%)
  • Figure 46 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 47 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 49 Infectious Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Autoimmune Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 51 Autoimmune Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Haematological Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 Haematological Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Cardiovascular Disorders Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 55 Cardiovascular Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 57 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 58 Biologics Market by Manufacturing Type: Market Attractiveness Index
  • Figure 59 Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 60 Biologics Share Forecast by Manufacturing Type, 2024, 2029, 2034 (%)
  • Figure 61 Outsource Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 62 Outsource Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 63 In-house Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 64 In-house Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 65 Biologics Market by End-users: Market Attractiveness Index
  • Figure 66 Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 67 Biologics Share Forecast by End-users, 2024, 2029, 2034 (%)
  • Figure 68 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 69 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 70 Speciality Centres Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 71 Speciality Centres Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 72 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 73 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 74 Biologics Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 75 Biologics Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 76 Biologics Market by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 North America Biologics Market Attractiveness Index
  • Figure 78 North America Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 79 North America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 North America Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 81 North America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 North America Biologics Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 83 North America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 84 North America Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 85 North America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 86 North America Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
  • Figure 87 North America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 88 North America Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 89 U.S. Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 90 Canada Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 91 Europe Biologics Market Attractiveness Index
  • Figure 92 Europe Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 93 Europe Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 94 Europe Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 95 Europe Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 Europe Biologics Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 97 Europe Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 Europe Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 99 Europe Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 Europe Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
  • Figure 101 Europe Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 Europe Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 103 Germany Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 104 UK Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 105 France Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 Italy Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 107 Spain Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 108 Russia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 109 Rest of Europe Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 110 Asia Biologics Market Attractiveness Index
  • Figure 111 Asia Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 112 Asia Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Asia Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 114 Asia Pacific Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 115 Asia Pacific Biologics Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 116 Asia Pacific Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 117 Asia Pacific Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 118 Asia Pacific Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 119 Asia Pacific Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
  • Figure 120 Asia Pacific Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 121 Asia Pacific Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 122 Japan Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 123 China Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 124 India Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 125 Australia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 126 South Korea Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 Rest of Asia Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 128 Latin America Biologics Market Attractiveness Index
  • Figure 129 Latin America Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 130 Latin America Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 131 Latin America Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 132 Latin America Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 133 Latin America Biologics Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 134 Latin America Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 135 Latin America Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 136 Latin America Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 137 Latin America Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
  • Figure 138 Latin America Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 139 Latin America Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 140 Brazil Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 141 Mexico Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 142 Argentina Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 143 Rest of Latin America Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 144 MEA Biologics Market Attractiveness Index
  • Figure 145 MEA Biologics Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 146 MEA Biologics Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 147 MEA Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 148 MEA Biologics Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
  • Figure 149 MEA Biologics Market Share Forecast by Product, 2024 & 2034 (%)
  • Figure 150 MEA Biologics Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 151 MEA Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 152 MEA Biologics Market Forecast by Manufacturing Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 153 MEA Biologics Market Share Forecast by Manufacturing Type, 2024 & 2034 (%)
  • Figure 154 MEA Biologics Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 155 MEA Biologics Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 156 GCC Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 157 South Africa Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 158 Rest of MEA Biologics Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 159 Biologics Market: Company Share Analysis, 2022
  • Figure 160 Johnson & Johnson: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 161 Johnson & Johnson: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 162 Johnson & Johnson: Regional Market Shares, 2022
  • Figure 163 Johnson & Johnson: Business Market Shares, 2022
  • Figure 164 F. Hoffmann-La Roche AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 165 F. Hoffmann-La Roche AG: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 166 F. Hoffmann-La Roche AG: Regional Market Shares, 2022
  • Figure 167 F. Hoffmann-La Roche AG: Business Market Shares, 2022
  • Figure 168 Amgen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 169 Amgen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 170 Amgen Inc.: Regional Market Shares, 2022
  • Figure 171 Amgen Inc.: Business Market Shares, 2022
  • Figure 172 AbbVie Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 173 AbbVie Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 174 AbbVie Inc.: Regional Market Shares, 2022
  • Figure 175 Novo Nordisk A/S: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 176 Novo Nordisk A/S: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 177 Novo Nordisk A/S: Regional Market Shares, 2022
  • Figure 178 Novo Nordisk A/S: Business Market Shares, 2022
  • Figure 179 Eli Lilly and Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 180 Eli Lilly and Company: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 181 Eli Lilly and Company: Regional Market Shares, 2022
  • Figure 182 Eli Lilly and Company: Business Market Shares, 2022
  • Figure 183 Bristol-Myers Squibb Company: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 184 Bristol-Myers Squibb Company: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 185 Bristol-Myers Squibb Company: Regional Market Shares, 2022
  • Figure 186 Bristol-Myers Squibb Company: Business Market Shares, 2022
  • Figure 187 Merck & Co.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 188 Merck & Co.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 189 Merck & Co.: Regional Market Shares, 2022
  • Figure 190 Merck & Co.: Business Market Shares, 2022
  • Figure 191 AstraZeneca plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 192 AstraZeneca plc: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 193 AstraZeneca plc: Regional Market Shares, 2022
  • Figure 194 AstraZeneca plc: Business Market Shares, 2022
  • Figure 195 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 196 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 197 Sanofi: Regional Market Shares, 2022
  • Figure 198 Sanofi: Business Market Shares, 2022
  • Figure 199 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 200 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 201 Pfizer Inc.: Regional Market Shares, 2023
  • Figure 202 Pfizer Inc.: Business Market Shares, 2022
  • Figure 203 Regeneron Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 204 Regeneron Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 205 Regeneron Pharmaceuticals, Inc.: Business Market Shares, 2022
  • Figure 206 Gilead Sciences, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 207 Gilead Sciences, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 208 Gilead Sciences, Inc.: Regional Market Shares, 2022
  • Figure 209 Gilead Sciences, Inc: Business Market Shares, 2022
  • Figure 210 Celltrion, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 211 Biogen Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 212 Biogen Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 213 Biogen Inc.: Regional Market Shares, 2022